French Pediatric Oncology Society Issues Cardiotoxicity Guidelines for Children With Acute Leukemia

SFCE guidelines: anthracycline-related heart failure affects ~10% of pediatric leukemia patients, especially at cumulative doses >300 mg/m² doxorubicin-equivalent. Dexrazoxane now recommended at that threshold. Global longitudinal strain preferred over ejection fraction for subc…

• Consensus guideline from the French Society of Childhood Cancer (SFCE) Leukemia Committee; not a prospective study — evidence synthesis with expert recommendations.
• A dedicated multidisciplinary 'heart team' (pediatric cardiologist + hematologist) is recommended to coordinate surveillance; tyrosine kinase inhibitors, immunotherapies, and CAR-T cells also flagged as cardiotoxic and requiring tailored monitoring.
• Key limitation: prospective pediatric data are sparse — the guideline explicitly calls for studies to define age-appropriate imaging thresholds, validate cardiac biomarkers, and assess liposomal anthracycline formulations.

RadPigeon summaries are original and for information only. They are not clinical advice.